Cargando…

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

PURPOSE/OBJECTIVE: Radiotherapy (RT) induces an immunogenic antitumor response, but also some immunosuppressive barriers. It remains unclear how different fractionation protocols can modulate the immune microenvironment. Clinical studies are ongoing to evaluate immune checkpoint inhibitors (ICI) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Grapin, Mathieu, Richard, Corentin, Limagne, Emeric, Boidot, Romain, Morgand, Véronique, Bertaut, Aurélie, Derangere, Valentin, Laurent, Pierre-Antoine, Thibaudin, Marion, Fumet, Jean David, Crehange, Gilles, Ghiringhelli, François, Mirjolet, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593525/
https://www.ncbi.nlm.nih.gov/pubmed/31238970
http://dx.doi.org/10.1186/s40425-019-0634-9
_version_ 1783430066311528448
author Grapin, Mathieu
Richard, Corentin
Limagne, Emeric
Boidot, Romain
Morgand, Véronique
Bertaut, Aurélie
Derangere, Valentin
Laurent, Pierre-Antoine
Thibaudin, Marion
Fumet, Jean David
Crehange, Gilles
Ghiringhelli, François
Mirjolet, Céline
author_facet Grapin, Mathieu
Richard, Corentin
Limagne, Emeric
Boidot, Romain
Morgand, Véronique
Bertaut, Aurélie
Derangere, Valentin
Laurent, Pierre-Antoine
Thibaudin, Marion
Fumet, Jean David
Crehange, Gilles
Ghiringhelli, François
Mirjolet, Céline
author_sort Grapin, Mathieu
collection PubMed
description PURPOSE/OBJECTIVE: Radiotherapy (RT) induces an immunogenic antitumor response, but also some immunosuppressive barriers. It remains unclear how different fractionation protocols can modulate the immune microenvironment. Clinical studies are ongoing to evaluate immune checkpoint inhibitors (ICI) in association with RT. However, only few trials aim to optimize the RT fractionation to improve efficacy of these associations. Here we sought to characterize the effect of different fractionation protocols on immune response with a view to associating them with ICI. MATERIALS/METHODS: Mice bearing subcutaneous CT26 colon tumors were irradiated using a SARRP device according to different radiation schemes with a same biologically effective dose. Mice were monitored for tumor growth. The radiation immune response (lymphoid, myeloid cells, lymphoid cytokines and immune checkpoint targets) was monitored by flow cytometry at different timepoints after treatment and by RNA sequencing analysis (RNAseq). The same radiation protocols were performed with and without inhibitors of immune checkpoints modulated by RT. RESULTS: In the absence of ICI, we showed that 18x2Gy and 3x8Gy induced the longest tumor growth delay compared to 1×16.4Gy. While 3x8Gy and 1×16.4Gy induced a lymphoid response (CD8(+) T-cells, Regulators T-cells), 18x2Gy induced a myeloid response (myeloid-derived suppressor cells, tumor-associated macrophages 2). The secretion of granzyme B by CD8(+) T cells was increased to a greater extent with 3x8Gy. The expression of PD-L1 by tumor cells was moderately increased by RT, but most durably with 18x2Gy. T cell immunoreceptor with Ig and ITIM domains (TIGIT) expression by CD8(+) T-cells was increased with 3x8Gy, but decreased with 18x2Gy. These results were also observed with RNAseq. RT was dramatically more effective with 3x8Gy compared to all the other treatments schemes when associated with anti-TIGIT and anti-PD-L1 (9/10 mice in complete response). The association of anti-PD-L1 and RT was also effective in the 18x2Gy group (8/12 mice in complete response). CONCLUSION: Each fractionation scheme induced different lymphoid and myeloid responses as well as various modulations of PD-L1 and TIGIT expression. Furthermore, 3x8Gy was the most effective protocol when associated with anti-PD-L1 and anti-TIGIT. This is the first study combining RT and anti-TIGIT with promising results; further studies are warranted. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0634-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6593525
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65935252019-07-09 Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination Grapin, Mathieu Richard, Corentin Limagne, Emeric Boidot, Romain Morgand, Véronique Bertaut, Aurélie Derangere, Valentin Laurent, Pierre-Antoine Thibaudin, Marion Fumet, Jean David Crehange, Gilles Ghiringhelli, François Mirjolet, Céline J Immunother Cancer Research Article PURPOSE/OBJECTIVE: Radiotherapy (RT) induces an immunogenic antitumor response, but also some immunosuppressive barriers. It remains unclear how different fractionation protocols can modulate the immune microenvironment. Clinical studies are ongoing to evaluate immune checkpoint inhibitors (ICI) in association with RT. However, only few trials aim to optimize the RT fractionation to improve efficacy of these associations. Here we sought to characterize the effect of different fractionation protocols on immune response with a view to associating them with ICI. MATERIALS/METHODS: Mice bearing subcutaneous CT26 colon tumors were irradiated using a SARRP device according to different radiation schemes with a same biologically effective dose. Mice were monitored for tumor growth. The radiation immune response (lymphoid, myeloid cells, lymphoid cytokines and immune checkpoint targets) was monitored by flow cytometry at different timepoints after treatment and by RNA sequencing analysis (RNAseq). The same radiation protocols were performed with and without inhibitors of immune checkpoints modulated by RT. RESULTS: In the absence of ICI, we showed that 18x2Gy and 3x8Gy induced the longest tumor growth delay compared to 1×16.4Gy. While 3x8Gy and 1×16.4Gy induced a lymphoid response (CD8(+) T-cells, Regulators T-cells), 18x2Gy induced a myeloid response (myeloid-derived suppressor cells, tumor-associated macrophages 2). The secretion of granzyme B by CD8(+) T cells was increased to a greater extent with 3x8Gy. The expression of PD-L1 by tumor cells was moderately increased by RT, but most durably with 18x2Gy. T cell immunoreceptor with Ig and ITIM domains (TIGIT) expression by CD8(+) T-cells was increased with 3x8Gy, but decreased with 18x2Gy. These results were also observed with RNAseq. RT was dramatically more effective with 3x8Gy compared to all the other treatments schemes when associated with anti-TIGIT and anti-PD-L1 (9/10 mice in complete response). The association of anti-PD-L1 and RT was also effective in the 18x2Gy group (8/12 mice in complete response). CONCLUSION: Each fractionation scheme induced different lymphoid and myeloid responses as well as various modulations of PD-L1 and TIGIT expression. Furthermore, 3x8Gy was the most effective protocol when associated with anti-PD-L1 and anti-TIGIT. This is the first study combining RT and anti-TIGIT with promising results; further studies are warranted. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0634-9) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-25 /pmc/articles/PMC6593525/ /pubmed/31238970 http://dx.doi.org/10.1186/s40425-019-0634-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Grapin, Mathieu
Richard, Corentin
Limagne, Emeric
Boidot, Romain
Morgand, Véronique
Bertaut, Aurélie
Derangere, Valentin
Laurent, Pierre-Antoine
Thibaudin, Marion
Fumet, Jean David
Crehange, Gilles
Ghiringhelli, François
Mirjolet, Céline
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
title Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
title_full Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
title_fullStr Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
title_full_unstemmed Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
title_short Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
title_sort optimized fractionated radiotherapy with anti-pd-l1 and anti-tigit: a promising new combination
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593525/
https://www.ncbi.nlm.nih.gov/pubmed/31238970
http://dx.doi.org/10.1186/s40425-019-0634-9
work_keys_str_mv AT grapinmathieu optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination
AT richardcorentin optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination
AT limagneemeric optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination
AT boidotromain optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination
AT morgandveronique optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination
AT bertautaurelie optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination
AT derangerevalentin optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination
AT laurentpierreantoine optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination
AT thibaudinmarion optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination
AT fumetjeandavid optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination
AT crehangegilles optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination
AT ghiringhellifrancois optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination
AT mirjoletceline optimizedfractionatedradiotherapywithantipdl1andantitigitapromisingnewcombination